Dr. Monsef Benkirane, from the Laboratoire de Virologie Moléculaire in Montpellier, France, has been announced as the recipient of the 2013 Retrovirology Prize. This biannual prize covers all aspects of the Retrovirology field and celebrates groundbreaking research from retrovirologists aged between 45 and 60. Monsef is among the brightest young "stars" in HIV-1 biology. At 45 years of age, he is the youngest recipient of the Retrovirology prize. This year the competition was particularly fierce with 4 strong contenders.
Monsef received training in immunology at the University of Marseille, France, and came to the laboratory of our former editor-in-chief Kuan-Teh Jeang at the NIH in 1995, where he worked on HIV-1 transcription and post transcriptional regulation. In 1998, Monsef established his own laboratory at the Human Genetics Institute in Montpellier, France. He published the first paper showing that the transcriptional activity of Tat is regulated by post-translational modifications such as acetylation and ubiquitylation [1, 2] . He also published a pioneering study on the identification of the subunit composition of the Positive Transcription Elongation Factor, PTEFb.
He focused on understanding the molecular mechanisms leading to the establishment and maintenance of transcriptionally silent HIV provirus, an important area of research for the design of virus eradication strategies (Cure for AIDS) [3] . His team provided the first demonstration of the role of the histone methyltransferase Suv39H1 in HIV-1 transcriptional silencing [4] . Additionally, he unraveled an intricate crosstalk between HIV transcription and the cellular RNAi machinery [5] [6] [7] .
Most recently, Monsef has worked on a puzzle that has occupied the study of HIV-1 for over 2 decades: why myeloid cell and quiescent CD4+ T cells are refractory to HIV-1 replication. He and his team have made ground breaking contributions in this field. They identified SAMHD1, a protein encoded by an Aicardi-Goutières Syndrome susceptibility gene, as the HIV-1 restriction factor operating in dendritic cells, macrophages and quiescent CD4+ T cells [8] . The identification of the restriction factor operating in these cells has been a very challenging and competitive area of research that received quite some attention in our journal recently [9] [10] [11] .
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